New lupus drug enters human testing
NCT ID NCT06625671
Summary
This early-stage study is testing a new drug called DB-2304 for lupus. It will first check the drug's safety and side effects in healthy volunteers, then in people with lupus. The main goal is to see how well the body tolerates the drug and how it behaves in the bloodstream.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site AUS01-0
COMPLETEDMelbourne, Victoria, 3004, Australia
-
US02-0
RECRUITINGSan Antonio, Texas, 78215, United States
-
US03-0
RECRUITINGClearwater, Florida, 33765, United States
-
US04-0
RECRUITINGIrving, Texas, 75061, United States
Conditions
Explore the condition pages connected to this study.